OPT-302: Completed Ph I/IIa enrollment

Opthea completed enrollment of 31 patients in the dose-expansion Phase IIa portion of a single-blind, U.S. Phase I/IIa trial evaluating once-monthly 2 mg intravitreal OPT-302 as monotherapy or in com...